Press Releases

Back to previous page

ReGen Biologics Participates in 2007 AAOS Annual Meeting

FRANKLIN LAKES, NJ -- Feb. 5, 2007 -- ReGen Biologics, Inc. (OTC:RGBI) today confirmed the company will exhibit the company’s products at this year’s American Academy of Orthopaedic Surgeons (AAOS) meeting, to be held in San Diego February 14-16.

In addition to the exhibit, data from its CMI™ product clinical trial will be featured during in podium presentations during AAOS Specialty Day on February 17.

“The AAOS provides an excellent forum for us to meet with surgeons from around the world, communicate our company goals, and share our latest clinical data,” said Gerald E. Bisbee, Jr., Ph.D., Chairman and Chief Executive Officer of ReGen Biologics.

The AAOS annual meeting, billed as “the crossroads of orthopaedic education, research, and technology”, has a pre-registration of over 10,400 physicians, including nearly 3000 from outside the United States.  For more information on the AAOS, its annual meeting, or scheduled presentations visit www.aaos.org.

About ReGen Biologics, Inc.
ReGen Biologics is a global orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products. ReGen's patented collagen scaffold technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery.  The Company’s first approved product using its collagen scaffold technology is the CMI™, a meniscus application cleared for sale in Europe and marketed through the Company’s European subsidiary, ReGen Biologics AG. ReGen has submitted a 510(k) to the FDA in the U.S. for clearance of the CMI.  ReGen Biologics is headquartered in Franklin Lakes, NJ and operates a manufacturing plant in Redwood City, CA. For more information on ReGen, visit www.regenbio.com.